Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension
Open Access
- 28 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 123 (25), 2985-2993
- https://doi.org/10.1161/circulationaha.110.015693
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease that causes exercise limitation, heart failure, and death. We aimed to determine the safety and efficacy of aspirin and simvastatin in PAH. We performed a randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH receiving background therapy at 4 centers. A total of 92 patients with PAH were to be randomized to aspirin 81 mg or matching placebo and simvastatin 40 mg or matching placebo. The primary outcome was 6-minute walk distance at 6 months. Sixty-five subjects had been randomized when the trial was terminated by the Data Safety and Monitoring Board after an interim analysis showed futility in reaching the primary end point for simvastatin. After adjustment for baseline 6-minute walk distance, there was no significant difference in the 6-minute walk distance at 6 months between aspirin (n=32) and placebo (n=33; placebo-corrected difference −0.5 m, 95% confidence interval −28.4 to 27.4 m; P =0.97) or between simvastatin (n=32) and placebo (n=33; placebo-corrected difference −27.6 m, 95% confidence interval −59.6 to 4.3 m; P =0.09). There tended to be more major bleeding episodes with aspirin than with placebo (4 events versus 1 event, respectively; P =0.17). Neither aspirin nor simvastatin had a significant effect on the 6-minute walk distance, although patients randomized to simvastatin tended to have a lower 6-minute walk distance at 6 months. These results do not support the routine treatment of patients with PAH with these medications. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00384865.Keywords
This publication has 44 references indexed in Scilit:
- Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2010
- Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled studyBrazilian Journal of Medical and Biological Research, 2008
- Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Oxidative Stress in Severe Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004
- 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27Published by Elsevier BV ,1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.JCI Insight, 1998
- Microangiopathic Hemolytic Anemia and Thrombocytopenia in a Child with Atrial Septal Defect and Pulmonary Hypertension.The Tohoku Journal of Experimental Medicine, 1997
- Circulating Platelet Aggregates Indicative of in Vivo Platelet Activation in Pulmonary HypertensionAngiology, 1993
- Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release AspirinNew England Journal of Medicine, 1991